Pseudomonas aeruginosa is an opportunistic pathogen often involved in airway infections of cystic fibrosis (CF) patients. Its pathogenicity is related to several virulence factors, such as biofilm formation, motility and production of toxins and proteases. The expression of these virulence factors is controlled by quorum sensing (QS). Thus, QS inhibition is considered a novel strategy for the development of antipathogenic compounds acting on specific bacterial virulence programs without affecting bacterial vitality. In this context, cold-adapted marine bacteria living in polar regions represent an untapped reservoir of biodiversity endowed with an interesting chemical repertoire. In this paper, we investigated the biological activity of a supernatant derived from a novel Antarctic bacterium (SN_TAE2020) against specific virulence factors produced by P. aeruginosa strains isolated from FC patients. Our results clearly show a reduction in pyocyanin and protease production in the presence of SN_TAE2020. Finally, SN_TAE2020 was also able to strongly affect swarming and swimming motility for almost all tested strains. Furthermore, the effect of SN_TAE2020 was investigated on biofilm growth and texture, captured by SEM analysis. In consideration of the novel results obtained on clinical strains, polar bacteria might represent potential candidates for the discovery of new compounds limiting P. aeruginosa virulence in CF patients.

Anti-virulence properties of the cell-free supernatant of the Antarctic bacterium Psychrobacter sp TAE2020 against Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients / Papa, R.; Vrenna, G.; D'Angelo, C.; Casillo, A.; Relucenti, M.; Donfrancesco, O.; Corsaro, M. M.; Vita Fiscarelli, E.; Tuccio Guarna Assanti, V.; Tutino, M. L.; Parrilli, E.; Artini, M.; Selan., L.. - In: ANTIBIOTICS. - ISSN 2079-6382. - 10:8(2021), pp. 944-962. [10.3390/antibiotics10080944]

Anti-virulence properties of the cell-free supernatant of the Antarctic bacterium Psychrobacter sp TAE2020 against Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients.

C. D'Angelo;A. Casillo;M. M. Corsaro;M. L. Tutino;E. Parrilli;
2021

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen often involved in airway infections of cystic fibrosis (CF) patients. Its pathogenicity is related to several virulence factors, such as biofilm formation, motility and production of toxins and proteases. The expression of these virulence factors is controlled by quorum sensing (QS). Thus, QS inhibition is considered a novel strategy for the development of antipathogenic compounds acting on specific bacterial virulence programs without affecting bacterial vitality. In this context, cold-adapted marine bacteria living in polar regions represent an untapped reservoir of biodiversity endowed with an interesting chemical repertoire. In this paper, we investigated the biological activity of a supernatant derived from a novel Antarctic bacterium (SN_TAE2020) against specific virulence factors produced by P. aeruginosa strains isolated from FC patients. Our results clearly show a reduction in pyocyanin and protease production in the presence of SN_TAE2020. Finally, SN_TAE2020 was also able to strongly affect swarming and swimming motility for almost all tested strains. Furthermore, the effect of SN_TAE2020 was investigated on biofilm growth and texture, captured by SEM analysis. In consideration of the novel results obtained on clinical strains, polar bacteria might represent potential candidates for the discovery of new compounds limiting P. aeruginosa virulence in CF patients.
2021
Anti-virulence properties of the cell-free supernatant of the Antarctic bacterium Psychrobacter sp TAE2020 against Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients / Papa, R.; Vrenna, G.; D'Angelo, C.; Casillo, A.; Relucenti, M.; Donfrancesco, O.; Corsaro, M. M.; Vita Fiscarelli, E.; Tuccio Guarna Assanti, V.; Tutino, M. L.; Parrilli, E.; Artini, M.; Selan., L.. - In: ANTIBIOTICS. - ISSN 2079-6382. - 10:8(2021), pp. 944-962. [10.3390/antibiotics10080944]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/856681
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact